These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1364158

  • 21. Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.
    Eckstein A, Esser J, Mann K, Schott M.
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():198-203. PubMed ID: 20467363
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L, Ceriani L, Garancini S.
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients.
    Szabó J, Leövey A, Karányi Z, Várvölgyi C, Fórizs E, Herceg L.
    Acta Med Hung; 1989 Mar; 46(1):23-30. PubMed ID: 2570399
    [Abstract] [Full Text] [Related]

  • 27. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C, Gibassier J, d'Herbomez M.
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [Abstract] [Full Text] [Related]

  • 30. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
    Hirooka Y, Li C, Takagi J, Gotoh M, Habu S, Yasaka-Nomura T, Ishihara R, Nakasone Y, Nakamura R, Morikawa R, Otake K, Nogimori T, Ishizuki Y.
    Int J Clin Pharmacol Res; 2004 Mar; 24(4):111-6. PubMed ID: 15754915
    [Abstract] [Full Text] [Related]

  • 31. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E, Antoine E, Nadalon S, Cevallos R, Bournaud E, Vandroux JC, Bordessoule D, Loustaud V, Weinbreck P, Liozon F.
    Ann Med Interne (Paris); 1988 Mar; 139(5):331-5. PubMed ID: 2462393
    [Abstract] [Full Text] [Related]

  • 32. Lymphocytes resided in the thyroid are the main source of TSH-receptor antibodies in Basedow's-Graves' disease?
    Leövey A, Nagy E, Balazs G, Bako G.
    Exp Clin Endocrinol; 1992 Mar; 99(3):147-50. PubMed ID: 1526264
    [Abstract] [Full Text] [Related]

  • 33. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y, Takeoka K, Amino N.
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [Abstract] [Full Text] [Related]

  • 34. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K.
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [Abstract] [Full Text] [Related]

  • 35. Improvement of immunologic abnormalities associated with hyperthyroidism of Graves' disease during methimazole treatment.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Ishihara M, Hasegawa Y, Ogata H, Kamoi K, Kaneko K.
    Horm Metab Res; 1988 Apr; 20(4):235-8. PubMed ID: 3397034
    [Abstract] [Full Text] [Related]

  • 36. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y, Tanigawa S, Ishikawa K, Hamada N.
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [Abstract] [Full Text] [Related]

  • 37. Humoral and cellular immunological factors as possible markers of clinical relapse in HLA-typed Graves' patients followed with time.
    Di Mario U, Vitillo M, Perfetti R, Mancuso M, Morellini M, Cappellacci S, Pozzilli P, Andreani D.
    Horm Metab Res; 1989 May; 21(5):267-71. PubMed ID: 2789166
    [Abstract] [Full Text] [Related]

  • 38. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M, Cantalamessa L.
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [Abstract] [Full Text] [Related]

  • 39. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L.
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [Abstract] [Full Text] [Related]

  • 40. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.
    Alnaqdy A, Al-Maskari M.
    Med Princ Pract; 2005 May; 14(4):209-12. PubMed ID: 15961927
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.